Press Releases
Jun 08, 2022
Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression
Jun 01, 2022
Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
May 26, 2022
Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting
May 05, 2022
Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Apr 11, 2022
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
Apr 08, 2022
Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
Apr 07, 2022
Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting
Apr 06, 2022
Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
Mar 08, 2022
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results Selected for an Oral Presentation at the 2022 AACR Annual Meeting
Mar 08, 2022
Bicycle Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference
Pagination
Displaying 1 - 10 of 13